Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT3ZS42)

DTT Name Phosphodiesterase 1B (PDE1B)
Synonyms
PDES1B; PDE1B1; CamPDE 1B; Cam-PDE 1B; Calcium/calmodulindependent 3',5'cyclicnucleotide phosphodiesterase 1B; Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B; 63 kDa CamPDE; 63 kDa Cam-PDE
Gene Name PDE1B
DTT Type
Patented-recorded target
 [1]
BioChemical Class
Phosphoric diester hydrolase
UniProt ID
PDE1B_HUMAN
TTD ID
T77613
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
EC Number
EC 3.1.4.17
Sequence
MELSPRSPPEMLEESDCPSPLELKSAPSKKMWIKLRSLLRYMVKQLENGEINIEELKKNL
EYTASLLEAVYIDETRQILDTEDELQELRSDAVPSEVRDWLASTFTQQARAKGRRAEEKP
KFRSIVHAVQAGIFVERMFRRTYTSVGPTYSTAVLNCLKNLDLWCFDVFSLNQAADDHAL
RTIVFELLTRHNLISRFKIPTVFLMSFLDALETGYGKYKNPYHNQIHAADVTQTVHCFLL
RTGMVHCLSEIELLAIIFAAAIHDYEHTGTTNSFHIQTKSECAIVYNDRSVLENHHISSV
FRLMQDDEMNIFINLTKDEFVELRALVIEMVLATDMSCHFQQVKTMKTALQQLERIDKPK
ALSLLLHAADISHPTKQWLVHSRWTKALMEEFFRQGDKEAELGLPFSPLCDRTSTLVAQS
QIGFIDFIVEPTFSVLTDVAEKSVQPLADEDSKSKNQPSFQWRQPSLDVEVGDPNPDVVS
FRSTWVKRIQENKQKWKERAASGITNQMSIDELSPCEEEAPPSPAEDEHNQNGNLD
Function
Has a preference for cGMP as a substrate. Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.
KEGG Pathway
Purine metabolism (hsa00230 )
Calcium signaling pathway (hsa04020 )
Morphine addiction (hsa05032 )
Reactome Pathway
G alpha (s) signalling events (R-HSA-418555 )
cGMP effects (R-HSA-418457 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
11 Patented Agent(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
AC1LDDOQ DMKTMCH N. A. N. A. Patented [2]
AC1MOZOL DM6293C N. A. N. A. Patented [3]
US10034861, Example 1 DMLJV01 N. A. N. A. Patented [4]
US10034861, Example 164 DM27SFD N. A. N. A. Patented [4]
US10034861, Example 165 DMD8FS5 N. A. N. A. Patented [4]
US10092575, Example 101 DMU8CAD N. A. N. A. Patented [2]
US10092575, Example 141 DMT47DF N. A. N. A. Patented [5]
US10092575, Example 158 DM7MNE2 N. A. N. A. Patented [2]
US9073936, 1 DMZD1L5 N. A. N. A. Patented [6]
US9073936, 2 DMZH3MX N. A. N. A. Patented [6]
US9073936, 3 DMS9W6O N. A. N. A. Patented [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 Patented Agent(s)
2 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
IC-041 DMRF5LU Cognitive impairment 6D71 Investigative [1]
SCH51866 DMCWSJP Discovery agent N.A. Investigative [7]
------------------------------------------------------------------------------------

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1295).
2 Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds. US10092575.
3 Inhibitors of phosphodiesterase 11 (PDE11). US9173884.
4 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors. US10034861.
5 Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6h)-ones. US10105367.
6 Organic compounds. US9598426.
7 Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor. J Cardiovasc Pharmacol. 1996 Dec;28(6):862-9.